Sana Biotechnology Statistics
Total Valuation
SANA has a market cap or net worth of $1.41 billion. The enterprise value is $1.42 billion.
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025, before market open.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SANA has 262.06 million shares outstanding. The number of shares has increased by 12.02% in one year.
| Current Share Class | 262.06M |
| Shares Outstanding | 262.06M |
| Shares Change (YoY) | +12.02% |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | 7.07% |
| Owned by Institutions (%) | 47.12% |
| Float | 172.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 10.10 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.47, with a Debt / Equity ratio of 0.70.
| Current Ratio | 2.47 |
| Quick Ratio | 2.17 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -109.12% and return on invested capital (ROIC) is -39.89%.
| Return on Equity (ROE) | -109.12% |
| Return on Assets (ROA) | -26.30% |
| Return on Invested Capital (ROIC) | -39.89% |
| Return on Capital Employed (ROCE) | -62.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.30M |
| Employee Count | 194 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.99% in the last 52 weeks. The beta is 1.91, so SANA's price volatility has been higher than the market average.
| Beta (5Y) | 1.91 |
| 52-Week Price Change | +36.99% |
| 50-Day Moving Average | 3.92 |
| 200-Day Moving Average | 3.06 |
| Relative Strength Index (RSI) | 59.91 |
| Average Volume (20 Days) | 6,722,600 |
Short Selling Information
The latest short interest is 30.60 million, so 11.68% of the outstanding shares have been sold short.
| Short Interest | 30.60M |
| Short Previous Month | 33.41M |
| Short % of Shares Out | 11.68% |
| Short % of Float | 17.72% |
| Short Ratio (days to cover) | 5.88 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -206.22M |
| Pretax Income | -252.18M |
| Net Income | -252.18M |
| EBITDA | -191.85M |
| EBIT | -206.22M |
| Earnings Per Share (EPS) | -$1.06 |
Full Income Statement Balance Sheet
The company has $72.67 million in cash and $85.49 million in debt, giving a net cash position of -$12.82 million or -$0.05 per share.
| Cash & Cash Equivalents | 72.67M |
| Total Debt | 85.49M |
| Net Cash | -12.82M |
| Net Cash Per Share | -$0.05 |
| Equity (Book Value) | 122.56M |
| Book Value Per Share | 0.53 |
| Working Capital | 49.06M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$180.74 million and capital expenditures -$4.55 million, giving a free cash flow of -$185.29 million.
| Operating Cash Flow | -180.74M |
| Capital Expenditures | -4.55M |
| Free Cash Flow | -185.29M |
| FCF Per Share | -$0.71 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SANA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.02% |
| Shareholder Yield | -12.02% |
| Earnings Yield | -17.92% |
| FCF Yield | -13.17% |
Dividend Details Analyst Forecast
The average price target for SANA is $8.00, which is 48.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | 48.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -12.38% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |